Page 119 - Read Online

Page 12 of 14 Kamal et al. J Cancer Metastasis Treat 2019;5:11 I http://dx.doi.org/10.20517/2394-4722.2018.89

19. Rip J, Schenk GJ, de Boer AG. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin Drug Deliv 2009;6:227-37.
20. Abbott NJ, Friedman A. Overview and introduction: The blood-brain barrier in health and disease. Epilepsia 2012;53:1-6.
21. Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov
2016;15:275-92.
22. Anderson A, Choy C, Neman J, Duenas MJ, Jandial R, et al. Metastatic breast cancer to the brain: a clinical primer for translational
investigation. Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2013.
23. Weber GF. Molecular mechanisms of metastasis. Cancer Lett 2008;270:181-90.
24. Banys-Paluchowski M, Krawczyk N, Meier-Stiegen F, Fehm T. Circulating tumor cells in breast cancer - current status and perspectives.
Crit Rev Oncol Hematol 2016;97:22-9.
25. Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. Drug resistance driven by cancer stem cells and their niche. Int J Mol Sci
2017;18:E2574.
26. Rahmathulla G, Toms SA, Weil RJ. The molecular biology of brain metastasis. J Oncol 2012;2012:723541.
27. Seoane J, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Mol Oncol 2014;8:1120-31.
28. Jin X, Mu P. Targeting breast cancer metastasis. Breast Cancer (Auckl) 2015;9:23-34.
29. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
30. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol 1994;56:423-35.
31. Cheng X, Hung MC. Breast cancer brain metastases. Cancer Metastasis Rev 2007;26:635-43.
32. Lee BC, Lee TH, Avraham S, Avraham HK. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor
1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2004;2:327-38.
33. Avraham HK, Jiang S, Fu Y, Nakshatri H, Ovadia H, et al. Angiopoietin-2 mediates blood-brain barrier impairment and colonization of
triple-negative breast cancer cells in brain. J Pathol 2014;232:369-81.
34. Ahmad SA, Liu W, Jung YD, Fan F, Wilson M, et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human
colon cancer. Cancer Res 2001;61:1255-9.
35. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XHF, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Cell 2014;156:1002-16.
36. Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer
cell 2016;30:836-48.
37. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17.
38. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, et al. Heterogeneous blood-tumor barrier permeability determines drug
efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010;16:5664-78.
39. Villanueva MT. Drug therapy: smuggling trastuzumab into the brain. Nat Rev Clin Oncol 2013;10:669.
40. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, et al. Disruption of the blood brain barrier by brain metastases of triple-negative and
basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010;116:302-8.
41. Brosnan EM, Anders CK. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann
Transl Med 2018;6:163.
42. ELAmrawy F, Othman AA, Adkins C, Helmy A, Nounou MI. Tailored nanocarriers and bioconjugates for combating glioblastoma and other
brain tumors. J Cancer Metastasis Treat 2016;2:112-22.
43. Kazantsev AG, Outeiro TF. Drug discovery for CNS disorders: from bench to bedside. CNS Neurol Disord Drug Targets 2010;9:668.
44. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010;37:48-57.
45. Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab 1997;17:713-31.
46. Barar J, Rafi MA, Pourseif MM, Omidi Y. Blood-brain barrier transport machineries and targeted therapy of brain diseases. BioImpacts
2016;6:225-48.
47. Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, et al. Advances in novel drug delivery strategies for breast cancer therapy. Artif Cells
Blood Substit Immobil Biotechnol 2010;38:230-49.
48. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation
of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92.
49. Kobayashi H, Turkbey B, Watanabe R, Choyke PL. Cancer drug delivery: considerations in the rational design of nanosized bioconjugates.
Bioconjug Chem 2014;25:2093-100.
50. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Experimental and molecular pathology 2009;86:215-23.
51. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol
2015;33:941-51.
52. Liechty WB, Peppas NA. Expert opinion: responsive polymer nanoparticles in cancer therapy. Eur J Pharm Biopharm 2012;80:241-6.
53. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov
2008;7:771-82.
54. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release
2012;161:175-87.
55. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, et al. Effective use of nanocarriers as drug delivery systems for the treatment of
selected tumors. Int J Nanomedicine 2017;12:7291-309.
56. Weissenbock A, Wirth M, Gabor F. WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. J Control
Release 2004;99:383-92.
57. Wesselinova D. Current major cancer targets for nanoparticle systems. Curr Cancer Drug Targets 2011;11:164-83.
58. De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 2008;3:133-49.
59. Perche F, Torchilin VP. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv